BCBS Nebraska

Does BCBS Nebraska cover Zepbound?

Quick answer · Weight Loss

BCBS Nebraska covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 30 or higher
  • ACA Marketplace: Covered with requirements. BMI of 30 or higher

Last verified June 2, 2026. Policy effective July 1, 2023. Source: policy-211.html. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What BCBS Nebraska requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (hypertension, type 2 diabetes mellitus, and dyslipidemia)
  • 3 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Initial approval - weight management

All of:

  • Patient is 18 years of age or older
  • History of participation in a medically supervised weight loss program (low-calorie diet, increased physical activity, behavioral modifications) for at least 3 months prior to initiating therapy
  • Patient is currently on and will continue a weight loss program of low-calorie diet, increased physical activity, and behavioral modifications
  • Requested agent will NOT be used in combination with another GLP-1 receptor agonist
  • Requested dose is within FDA approved dosage limits
  • Requested agent will NOT be used in combination with another weight loss agent

Plus any one of:

  • BMI >= 30 kg/m2 (obesity diagnosis)
  • BMI >= 27 kg/m2 with at least one weight-related comorbidity/risk factor (e.g., diabetes, dyslipidemia, coronary artery disease)

Documentation to bring

  • Documentation of BMI >= 30 kg/m2 OR BMI >= 27 kg/m2 with qualifying comorbidity
  • Documentation of at least 3-month history of participation in a medically supervised weight loss program (low-calorie diet, increased physical activity, behavioral modifications)
  • Attestation that patient is currently on and will continue a weight loss program

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Provider must attest that patient has achieved and maintained weight loss >= 5% from baseline (prior to initiation of requested agent). Patient must be currently on and will continue a weight loss regimen. The 3-month medically supervised program requirement is not re-verified at renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Combination with another GLP-1 receptor agonist not permitted
  • Combination with another weight loss agent not permitted
  • Bariatric surgery

Policy note: Zepbound added to policy 04-01-2024. Policy description incorrectly labels Zepbound as liraglutide; Zepbound is actually tirzepatide. The weight loss criteria apply under the shared 'Target Agent(s)' framework.

Policy effective July 1, 2023 · verified June 2, 2026 · source: policy-211.html

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (hypertension, type 2 diabetes mellitus, and dyslipidemia)
  • 3 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Initial approval - weight management

All of:

  • Patient is 18 years of age or older
  • History of participation in a medically supervised weight loss program (low-calorie diet, increased physical activity, behavioral modifications) for at least 3 months prior to initiating therapy
  • Patient is currently on and will continue a weight loss program of low-calorie diet, increased physical activity, and behavioral modifications
  • Requested agent will NOT be used in combination with another GLP-1 receptor agonist
  • Requested dose is within FDA approved dosage limits
  • Requested agent will NOT be used in combination with another weight loss agent

Plus any one of:

  • BMI >= 30 kg/m2 (obesity diagnosis)
  • BMI >= 27 kg/m2 with at least one weight-related comorbidity/risk factor (e.g., diabetes, dyslipidemia, coronary artery disease)

Documentation to bring

  • Documentation of BMI >= 30 kg/m2 OR BMI >= 27 kg/m2 with qualifying comorbidity
  • Documentation of at least 3-month history of participation in a medically supervised weight loss program (low-calorie diet, increased physical activity, behavioral modifications)
  • Attestation that patient is currently on and will continue a weight loss program

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Provider must attest that patient has achieved and maintained weight loss >= 5% from baseline (prior to initiation of requested agent). Patient must be currently on and will continue a weight loss regimen. The 3-month medically supervised program requirement is not re-verified at renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Combination with another GLP-1 receptor agonist not permitted
  • Combination with another weight loss agent not permitted
  • Bariatric surgery

Policy note: Zepbound added to policy 04-01-2024. Policy description incorrectly labels Zepbound as liraglutide; Zepbound is actually tirzepatide. The weight loss criteria apply under the shared 'Target Agent(s)' framework.

Policy effective July 1, 2023 · verified June 2, 2026 · source: policy-211.html

Zepbound for Osa

What BCBS Nebraska requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Initial approval - OSA

All of:

  • OSA diagnosis confirmed by polysomnography (PSG) or home sleep apnea test
  • AHI >= 15 events/hour from baseline (prior to initiation of pharmacotherapy)
  • Requested agent is Zepbound
  • BMI >= 30 kg/m2
  • Patient does not have craniofacial abnormalities that may affect breathing
  • Patient does NOT have diagnosis of central or mixed sleep apnea with mixed or central apneas/hypopneas >= 50%
  • Patient does NOT have diagnosis of Cheyne Stokes Respiration
  • Patient does NOT have diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
  • Patient is not pregnant
  • Requested agent will NOT be used in combination with another GLP-1 receptor agonist
  • Requested agent will NOT be used in combination with another weight loss agent

Documentation to bring

  • Polysomnography (PSG) or home sleep apnea test results confirming OSA diagnosis
  • Documentation of AHI >= 15 events/hour at baseline
  • Documentation of BMI >= 30 kg/m2
  • Documentation that patient does not have craniofacial abnormalities affecting breathing
  • Documentation that patient does not have central/mixed sleep apnea (>= 50% central/mixed apneas/hypopneas)
  • Documentation that patient does not have Cheyne Stokes Respiration
  • Documentation that patient does not have Obesity Hypoventilation Syndrome or daytime hypercapnia

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must demonstrate clinical benefit with requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). Patient must not be pregnant and not currently treated with another GLP-1 receptor agonist.

Not covered when

  • Craniofacial abnormalities that may affect breathing
  • Central or mixed sleep apnea with mixed or central apneas/hypopneas >= 50%
  • Cheyne Stokes Respiration
  • Obesity Hypoventilation Syndrome or daytime hypercapnia
  • Combination with another GLP-1 receptor agonist not permitted
  • Combination with another weight loss agent not permitted
  • Pregnancy

Policy note: OSA criteria added 06-30-2025. Only Zepbound is eligible for the OSA indication per policy. No PAP/CPAP prior trial required. Renewal requires clinical benefit evidence (e.g., AHI reduction or improved Epworth Sleepiness Scale score).

Policy effective July 1, 2023 · verified June 2, 2026 · source: policy-211.html

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Initial approval - OSA

All of:

  • OSA diagnosis confirmed by polysomnography (PSG) or home sleep apnea test
  • AHI >= 15 events/hour from baseline (prior to initiation of pharmacotherapy)
  • Requested agent is Zepbound
  • BMI >= 30 kg/m2
  • Patient does not have craniofacial abnormalities that may affect breathing
  • Patient does NOT have diagnosis of central or mixed sleep apnea with mixed or central apneas/hypopneas >= 50%
  • Patient does NOT have diagnosis of Cheyne Stokes Respiration
  • Patient does NOT have diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
  • Patient is not pregnant
  • Requested agent will NOT be used in combination with another GLP-1 receptor agonist
  • Requested agent will NOT be used in combination with another weight loss agent

Documentation to bring

  • Polysomnography (PSG) or home sleep apnea test results confirming OSA diagnosis
  • Documentation of AHI >= 15 events/hour at baseline
  • Documentation of BMI >= 30 kg/m2
  • Documentation that patient does not have craniofacial abnormalities affecting breathing
  • Documentation that patient does not have central/mixed sleep apnea (>= 50% central/mixed apneas/hypopneas)
  • Documentation that patient does not have Cheyne Stokes Respiration
  • Documentation that patient does not have Obesity Hypoventilation Syndrome or daytime hypercapnia

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must demonstrate clinical benefit with requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). Patient must not be pregnant and not currently treated with another GLP-1 receptor agonist.

Not covered when

  • Craniofacial abnormalities that may affect breathing
  • Central or mixed sleep apnea with mixed or central apneas/hypopneas >= 50%
  • Cheyne Stokes Respiration
  • Obesity Hypoventilation Syndrome or daytime hypercapnia
  • Combination with another GLP-1 receptor agonist not permitted
  • Combination with another weight loss agent not permitted
  • Pregnancy

Policy note: OSA criteria added 06-30-2025. Only Zepbound is eligible for the OSA indication per policy. No PAP/CPAP prior trial required. Renewal requires clinical benefit evidence (e.g., AHI reduction or improved Epworth Sleepiness Scale score).

Policy effective July 1, 2023 · verified June 2, 2026 · source: policy-211.html

Why Zepbound requests get denied by BCBS Nebraska

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. No documented diet and exercise program.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does BCBS Nebraska cover Zepbound?
BCBS Nebraska covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
What BMI do you need for Zepbound under BCBS Nebraska?
For weight loss on Employer / Commercial Insurance plans, BCBS Nebraska requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.
How long does a Zepbound approval last with BCBS Nebraska?
Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does BCBS Nebraska require to renew Zepbound?
At least 5% weight loss from the starting weight and Provider must attest that patient has achieved and maintained weight loss >= 5% from baseline (prior to initiation of requested agent). Patient must be currently on and will continue a weight loss regimen. The 3-month medically supervised program requirement is not re-verified at renewal.
How current is this information?
This page reflects BCBS Nebraska's written policy as of July 1, 2023, last verified against the source document on June 2, 2026.

Other medications under BCBS Nebraska

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Nebraska's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.